F7
ENSG00000057593
Target class
Enzyme
Chromosome
13
Approved drugs
3
Clinical candidates (approved and in development)
6
- Approved drugs
- 3
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- Yes
- Target name
- F7
- Gene name
- Coagulation factor VII
- Gene symbol
- F7
- Protein name
- Coagulation factor VII (EC 3.4.21.21) (Proconvertin) (Serum prothrombin conversion accelerator) (SPCA) (Eptacog alfa) [Cleaved into: Factor VII light chain; Factor VII heavy chain]
- Gene biotype
- Protein coding
- Gene family
- Gla domain containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 8
- Highest tissue expression
- 83.64
- Tissue specificity (Gini)
- 0.878
- Tissue specificity (tau)
- 0.994
- KEGG gene identifiers
- hsa:2155
- Protein interaction confidence
- 0.844345
- Protein interaction partners
- 29
- R-HSA-1368108
- R-HSA-159740
- R-HSA-159763
- R-HSA-159782
- R-HSA-9769735
- R-HSA-9769739
- End position
- 113120685
- Start position
- 113105762
- Chromosome
- 13
- Strand
- Forward
- Secreted .
Publication evidence
- PubMed 36951360
- Tissue specificity (tau)
- 0.994338
- Expression inequality (Gini)
- 0.878303
Expression in transcripts per million
- Liver
- 83.64
- Testis
- 3.25
- Cervix - Ectocervix
- 1.94
- Brain - Cerebellum
- 1.58
- Brain - Frontal Cortex (BA9)
- 1.51
Expression in transcripts per million
- Liver83.64
- Testis3.25
- Cervix - Ectocervix1.94
- Brain - Cerebellum1.58
- Brain - Frontal Cortex (BA9)1.51
- Cervix - Endocervix1.46
- Brain - Cortex1.36
- Brain - Cerebellar Hemisphere1.13
- Brain - Anterior cingulate cortex (BA24)0.87
- Vagina0.74
- Pituitary0.72
- Ovary0.69
- Fallopian Tube0.66
- Brain - Hypothalamus0.59
- Brain - Nucleus accumbens (basal ganglia)0.56
- Prostate0.54
- Skin - Sun Exposed (Lower leg)0.52
- Small Intestine - Terminal Ileum0.49
- Brain - Caudate (basal ganglia)0.45
- Skin - Not Sun Exposed (Suprapubic)0.43
- Minor Salivary Gland0.39
- Kidney - Medulla0.38
- Brain - Putamen (basal ganglia)0.38
- Kidney - Cortex0.32
- Breast - Mammary Tissue0.31
And 29 more, listed on the interactive page.
- GO:0002690
- GO:0007596
- GO:0010641
- GO:0016485
- GO:0030335
- GO:0032008
- GO:0050927
- GO:0005576
- GO:0005788
- GO:0005796
- GO:0005886
- GO:0031012
- GO:1905286
- GO:0004252
- GO:0005515
- GO:0008236
Related records
Trials (142)
- "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
- "Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy
- A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor
- A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
- A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150
- A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India
- A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
- A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
- A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
- A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
- A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
- A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
- A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
- A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
- A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
- Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
- Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
- Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
Drugs (6)
- Coagulation factor VII human Coagulation factor VII exogenous protein
- Eptacog alfa (activated) Coagulation factor VII exogenous protein
- Eptacog alfa pegol (activated) Coagulation factor VII exogenous protein
- Eptacog beta (activated) Coagulation factor VII exogenous protein
- PCI-27483 Coagulation factor VII inhibitor
- Prothrombin complex concentrate Coagulation factor VII exogenous protein